Godavari Drugs MD, chairman, board of directors and AGM
BSE: 530317Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹124.15.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹122 Cr3,042nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 29.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 1.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 7.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 4.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 1.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,422
Godavari Drugs board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonGHANSHYAM JAJURelated to the promoter
- Managing directorMUKUND KAKANI
6 directors3 independent2 executive1 non-executive
- GHANSHYAM JAJU · ChairpersonNon-executive · joined Dec 1987 · reappointed Dec 2022 · 463 months as independent · 1 listed board · 2 committee seats
- MUKUND KAKANI · Managing directorExecutive · joined Sep 2006 · reappointed May 2022 · 237 months as independent · 1 listed board
- MOHIT JAJUExecutive · joined May 2010 · reappointed May 2022 · 194 months as independent · 1 listed board · 1 committee seat
- MAHENDRA UDAY BHALERAOIndependent · joined Nov 2022 · reappointed Dec 2022 · 287 months as independent · 1 listed board · 1 as independent · 3 committee seats, 2 as chair
- DINESH UDPAIndependent · joined Feb 2024 · 32 months as independent · 1 listed board · 1 as independent
- SHILPA BUNGIndependent · joined May 2025 · 16 months as independent · 3 listed boards · 3 as independent · 4 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- VIMALA BEHRAM MADON, left 23 Jun 2025: Tenure Completion
- SYED ANIS HUSSAIN, left 23 Jun 2025: Tenure Completion
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 31 Aug 20266 of 6 present3 independent · 16 days in between
- 14 Aug 20266 of 6 present3 independent · 78 days in between
- 27 May 20266 of 6 present3 independent
Audit Committee
Chair MAHENDRA UDAY BHALERAO
MOHIT JAJU, DINESH UDPA
- 14 Aug 20263 of 3 present2 independent · 78 days in between
- 27 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair DINESH UDPA
GHANSHYAM JAJU, MAHENDRA UDAY BHALERAO
- 27 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair MAHENDRA UDAY BHALERAO
GHANSHYAM JAJU, SHILPA BUNG
- 27 May 20263 of 3 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- Ayyadevara & CoPeer-review certificate valid to Oct 2028
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Godavari Drugs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Godavari Drugs share news and announcements
Annual general meeting, 25 Sep 2026
7,300 shareholders on the register on 18 Sep 2026; present: 9 promoters and 77 others; votes counted by VIDYA HARKUT / M/s. VSS & Associates.The company's voting result (opens in a new tab)
1. To receive, consider and adopt the audited standalone financial statement of the Company for the year ended March 31, 2026 together with the reports of the Board of directors and Auditors thereon and RESOLVED THAT the audited standalone financial statements of the Company for the financial year ended March 31, 2026 and the reports of the Board of directors and Auditors thereon, as circulated to the members be and are hereby considered and adopted.MoreLess
Ordinary99.96% for0.04% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.64%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
2. To appoint a director in place of Mr. Ghanshyam Jaju (DIN: 00104601), who retires by rotation and being eligible, offers himself for re-appointment and in this regard to consider and if thought fit, to pass the following resolution as an Ordinary Resolution RESOLVED THAT in accordance with the provisions of section 152 and other applicable provisions of the Companies Act, 2013, Mr. Ghanshyam Jaju (DIN: 00104601), Non-Executive Non Independent Director, who retires by rotation at this meeting and being eligible has offered himself for reappointment, be and is hereby appointed as Director of the CompanyMoreLess
Ordinary99.96% for0.04% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.64%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
3. To ratify the remuneration of Cost Auditors for the financial year ending March 31, 2027 and to consider and, if thought fit, to pass the following resolution as an Ordinary Resolution RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 (Act) and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modifications (s) or re-enactment thereof, for the time being in force), Ms. Bharathula and Associates (Membership no. 13760), Cost Accountants, were appointed by the Board of Directors on the recommendation of the Audit Committee of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2027, be paid the remuneration as set out in the Statement annexed to the notice convening this meeting. RESOLVED FURTHER THAT the Board of Directors and the Company Secretary of the Company be and are hereby authorized severally to perform all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.MoreLess
Ordinary99.96% for0.04% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.64%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
4. Alteration of Main Objects Clause IIIA of the Memorandum of Association of the Company and to consider and, if thought fit, to pass the following resolution as an Special Resolution RESOLVED THAT pursuant to the provisions of Section 13 and other applicable provisions of the Companies Act, 2013, read with the Companies Incorporation Rules, 2014 including any statutory modifications or re-enactment thereof for the time being in force and subject to such approvals, consents and permissions as may be necessary, consent of the Members of the Company be and is hereby accorded to alter the Main Objects Clause IIIA of the Memorandum of Association of the Company by inserting the following as a new Main Object No. 4 after the existing Main Object No. 3 To manufacture, process, formulate, purchase, sell, import, export, market and distribute nutraceuticals, dietary supplements, health supplements, natural extracts, herbal extracts, botanical extracts, standardised plant extracts, food ingredients, food additives, functional foods and allied products, whether through own manufacturing, third-party contract manufacturing or on loan license basis. RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) be and is hereby authorised to do all such acts, deeds and things and to take all such steps as may be required to give effect to this resolution, including filing of the requisite forms with the Registrar of Companies, Telangana, and to do all things as may be necessary, proper or expedient for the purpose of giving effect to this resolution.MoreLess
Special99.96% for0.04% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.64%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesMar 2026 | 44.12 | Capital Expenditure for the purpose of manufacturing Active, pharmaceutical Ingredients and intermediates, specialty chemicals in various therapeutic categories including Anti HIV and CNS segments as detailed below: a) Civil construction for production blocks, utilities, platforms, supports, foundations for equipments including finishing consisting of flooring, painting, etc.; b) Procurement and installation of equipments like reactors, heat exchangers, filtration equipments, dryers, pumps, pipelines and fittings, structural steel, safety equipments, fire fighting equipments, enhancement of capacity and upgradation of effluent treatment facilities, etc.; c) Augmenting the electrical infrastructure right from incoming line from substation to transformer and distribution upto the equipments consisting of transformers, electrical pannels, cables, lighting, earthing, etc. Erection and commissioning of all the above | 110.00 | 7.63 | No |
| Preferential IssuesMar 2026 | 44.12 | Working Capital Requirement | 17.12 | 0.00 | No |
| Preferential IssuesMar 2026 | 44.12 | Repayment of unsecured loans to promoters and / or Directors | 16.00 | 0.00 | No |